Memantine Mylan (Memantine Hydrochloride)

Memantine blocks the NMDA‑type glutamate receptor’s ion channel in a non‑competitive manner, reducing excessive calcium influx that can cause excitotoxic neuronal damage. This modulation helps protect neurons and may slow cognitive decline associated with neurodegenerative disease.

The specific dose and titration schedule for Memantine Mylan are determined by the prescribing clinician based on the patient’s condition, renal function, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for memantine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Memantine Mylan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas other approved agents such as donepezil, rivastigmine, and galantamine are acetylcholinesterase inhibitors. Memantine targets glutamatergic excitotoxicity, offering a different mechanism that can be used alone or in combination with acetylcholinesterase inhibitors for broader symptom control.

Memantine Mylan should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Memantine Mylan is taken orally, usually as a tablet, with or without food. The exact administration schedule, including any dose titration, is prescribed by the treating physician and should be followed precisely.

Serious risks include the potential for seizures, severe allergic reactions such as rash or angioedema, hallucinations or psychotic symptoms, and cardiac arrhythmias. Patients should seek immediate medical attention if any of these events occur.

Memantine Mylan is contraindicated in patients with known hypersensitivity to memantine hydrochloride or any of the tablet’s excipients. Caution is advised for individuals with severe renal impairment, uncontrolled epilepsy, or significant psychiatric disorders, and the drug should be avoided unless a clinician determines it is appropriate.